Back to top
more

BioLife Solutions (BLFS)

(Real Time Quote from BATS)

$20.71 USD

20.71
82,677

+1.40 (7.25%)

Updated Jul 11, 2024 11:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (169 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BLFS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for BioLife Solutions, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 52 63 70 90 6
Receivables 19 34 23 8 5
Notes Receivable 0 0 0 0 0
Inventories 43 35 28 12 11
Other Current Assets 7 7 4 5 1
Total Current Assets 121 138 126 115 24
Net Property & Equipment 21 24 18 10 6
Investments & Advances 6 6 4 6 3
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 246 257 377 90 56
Deposits & Other Assets 8 9 10 5 4
Total Assets 413 450 554 235 93
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 7 15 15 4 3
Current Portion Long-Term Debt 7 2 1 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 12 10 7 5 3
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 13 15 15 5 0
Total Current Liabilities 42 45 40 16 8
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 5 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 18 24 6 0 0
Non-Current Capital Leases 1 0 0 0 0
Other Non-Current Liabilities 0 2 5 5 41
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 75 86 74 30 49
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 651 612 585 303 143
Retained Earnings -313 -247 -105 -97 -100
Other Equity 0 -1 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 338 364 480 205 43
Total Liabilities & Shareholder's Equity 413 450 554 235 93
Total Common Equity 338 364 480 205 43
Shares Outstanding 44.00 42.70 40.70 32.70 20.40
Book Value Per Share 7.67 8.53 11.80 6.28 2.13

Fiscal Year End for BioLife Solutions, Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 45 52 41 46
Receivables NA 19 19 25 27
Notes Receivable NA 0 0 0 0
Inventories NA 43 43 43 39
Other Current Assets NA 4 7 8 8
Total Current Assets NA 112 121 117 120
Net Property & Equipment NA 21 21 21 26
Investments & Advances NA 6 6 6 7
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 245 246 247 254
Deposits & Other Assets NA 7 8 8 10
Total Assets NA 402 413 411 433
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 5 7 12 11
Current Portion Long-Term Debt NA 9 7 5 2
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 9 12 9 10
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 13 13 14 14
Total Current Liabilities NA 39 42 43 40
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 16 18 21 24
Non-Current Capital Leases NA 1 1 1 1
Other Non-Current Liabilities NA 0 0 2
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 68 75 79 81
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 659 651 633 623
Retained Earnings NA -325 -313 -300 -271
Other Equity NA -1 0 -1 -1
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 333 338 332 352
Total Liabilities & Shareholder's Equity NA 402 413 411 433
Total Common Equity 0 333 338 332 352
Shares Outstanding 46.00 45.30 44.00 43.40 43.40
Book Value Per Share 0.00 7.36 7.67 7.65 8.11